Soquelitinib for Peripheral T-Cell Lymphoma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called soquelitinib for certain types of T-cell lymphoma, a cancer affecting the immune system's T-cells. The trial compares soquelitinib to standard treatments selected by doctors to determine which is more effective for individuals whose cancer has returned or resisted other treatments. Participants will either take soquelitinib pills or receive standard care for up to two years. This trial may suit those with T-cell lymphoma that has been difficult to treat with previous therapies and who are ready to try a new option. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to access a potentially groundbreaking treatment.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, it mentions that participants should not have had monoclonal antibody therapy, radiotherapy, or chemotherapy within 3 weeks, and targeted therapy within 2 weeks before starting the study treatment.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Why do researchers think this study treatment might be promising?
Unlike the standard treatments for Peripheral T-Cell Lymphoma, which include drugs like pralatrexate and belinostat, Soquelitinib is a new oral medication that targets this condition differently. Soquelitinib is unique because it is taken orally twice a day and may offer a more convenient option compared to other treatments that often require intravenous administration. Researchers are excited about Soquelitinib because it could potentially improve patient outcomes with a new mechanism of action that targets specific pathways within the cancer cells, potentially leading to more effective and tailored treatment options.
What evidence suggests that this trial's treatments could be effective for peripheral T-cell lymphoma?
This trial will compare soquelitinib with standard treatments for peripheral T-cell lymphoma (PTCL). Research has shown that soquelitinib might help treat PTCL by targeting a specific protein in T-cells called ITK. In earlier studies, soquelitinib showed promising results in reducing T-cell exhaustion, potentially enhancing the immune system's ability to fight cancer. Patients treated with soquelitinib demonstrated improved outcomes, suggesting it may benefit those with T-cell lymphomas. Data from these studies offer hope that soquelitinib could be an effective option for treating this type of cancer.36789
Who Is on the Research Team?
Suresh Mahabhashyam, MD, MPH
Principal Investigator
Corvus Pharmaceuticals, Inc.
Are You a Good Fit for This Trial?
This trial is for adults over 18 with certain types of T-cell lymphoma who have tried up to three treatments that didn't work or they couldn't tolerate. They should be relatively active (able to care for themselves), have a life expectancy over 12 weeks, and their cancer must show on scans.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either soquelitinib or physician's choice standard of care treatment for up to 2 years
Follow-up
Participants are monitored for safety and effectiveness after treatment
Crossover
Participants on standard of care with disease progression may crossover to receive soquelitinib
What Are the Treatments Tested in This Trial?
Interventions
- Soquelitinib
Find a Clinic Near You
Who Is Running the Clinical Trial?
Corvus Pharmaceuticals, Inc.
Lead Sponsor